Gilead Sciences Inc. (GILD)

68.48
NASDAQ : Health Technology
Prev Close 68.84
Day Low/High 68.12 / 69.98
52 Wk Low/High 60.32 / 79.61
Avg Volume 6.41M
Exchange NASDAQ
Shares Outstanding 1.27B
Market Cap 87.53B
EPS 4.20
P/E Ratio 9.78
Div & Yield 2.52 (3.37%)

Latest News

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Kite Announces New Yescarta® Data From ZUMA-1

Kite Announces New Yescarta® Data From ZUMA-1

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses from the ZUMA-1 trial of Yescarta ® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma.

Kite Announces End Of Phase 1 ZUMA-3 Results For KTE-X19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite Announces End Of Phase 1 ZUMA-3 Results For KTE-X19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy.

Kite And Humanigen Announce Clinical Collaboration To Evaluate Investigational Combination Of Yescarta® (Axicabtagene Ciloleucel) With Lenzilumab In Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kite And Humanigen Announce Clinical Collaboration To Evaluate Investigational Combination Of Yescarta® (Axicabtagene Ciloleucel) With Lenzilumab In Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta ® (axicabtagene...

Gilead And Galapagos To Present Latest Data On Filgotinib At The Annual European Congress Of Rheumatology (EULAR 2019)

Gilead And Galapagos To Present Latest Data On Filgotinib At The Annual European Congress Of Rheumatology (EULAR 2019)

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in...

Gilead Sciences Appoints Johanna Mercier As Chief Commercial Officer

Gilead Sciences Appoints Johanna Mercier As Chief Commercial Officer

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Johanna Mercier will join the company as Chief Commercial Officer, and will become a member of the company's senior leadership team.

Gilead Sciences Slips on Goldman's Downgrade to Sell

Gilead Sciences Slips on Goldman's Downgrade to Sell

Shares of Gilead Sciences fall after Goldman Sachs downgrades the stock to sell from neutral.

Gilead Sciences To Present At The Jefferies 2019 Global Healthcare Conference On Wednesday, June 5

Gilead Sciences To Present At The Jefferies 2019 Global Healthcare Conference On Wednesday, June 5

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O'Day, Gilead's Chairman and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2019 Global Healthcare Conference in New York on Wednesday, June 5 at 11:30 a.

Kite To Present New Data From Leading Cell Therapy Portfolio At ASCO 2019

Kite To Present New Data From Leading Cell Therapy Portfolio At ASCO 2019

Kite, a Gilead Company (Nasdaq: GILD), today announced that new data from its cell therapy programs will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from May 31 - June 4, 2019.

Gilead Sciences To Provide Free Truvada For PrEP® To Support U.S. Initiative To End The HIV Epidemic

Gilead Sciences To Provide Free Truvada For PrEP® To Support U.S. Initiative To End The HIV Epidemic

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP ® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.

Gilead Sciences And Goldfinch Bio Announce Strategic Collaboration To Develop Novel Therapies For Kidney Disease

Gilead Sciences And Goldfinch Bio Announce Strategic Collaboration To Develop Novel Therapies For Kidney Disease

Gilead Sciences, Inc. (Nasdaq: GILD) and Goldfinch Bio, Inc.

Gilead Sciences To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference On Tuesday, May 14

Gilead Sciences To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference On Tuesday, May 14

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L.

Gilead Sciences Has Right Prescription on First-Quarter Earnings

Gilead Sciences Has Right Prescription on First-Quarter Earnings

Gilead Sciences' adjusted earnings in the first quarter beat analysts' expectations.

Gilead Sciences Is Regaining Its Shine

Gilead Sciences Is Regaining Its Shine

Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.

Gilead Sciences Announces Second Quarter 2019 Dividend

Gilead Sciences Announces Second Quarter 2019 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces First Quarter 2019 Financial Results

Gilead Sciences Announces First Quarter 2019 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2019.

Qualcomm, Dow Inc., Square, Beyond Meat, Jerome Powell - 5 Things You Must Know

Qualcomm, Dow Inc., Square, Beyond Meat, Jerome Powell - 5 Things You Must Know

U.S. stock futures are higher, rebounding from declines in the previous session after a policy statement from the Federal Reserve suggested U.S. interest rates likely will remain unchanged for the better part of the year; Qualcomm tumbles after forecasting weaker-than-expected third-quarter revenue; Square issues a weak earnings forecast for the second quarter; Beyond Meat's IPO is priced at $25 a share.

Gilead Sciences Expected to Earn $1.61 a Share

Gilead Sciences Expected to Earn $1.61 a Share

Gilead Sciences revenue expected to rise 4.1% to $5.3 billion.

Gilead Sciences' Chief Financial Officer Robin Washington To Step Down In Early 2020

Gilead Sciences' Chief Financial Officer Robin Washington To Step Down In Early 2020

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Robin Washington, Executive Vice President (EVP) and Chief Financial Officer (CFO), plans to retire from her role, effective March 1, 2020.

Feels Like Deja Tuesday

Friday felt a lot like Tuesday -- in that it didn’t change any of the big indicators -- but we should still pay close attention to the Citigroup Panic/Euphoria Index, which is now kissing the underside of Euphoria.

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study Of Selonsertib In Bridging Fibrosis (F3) Due To Nonalcoholic Steatohepatitis (NASH)

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study Of Selonsertib In Bridging Fibrosis (F3) Due To Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis...

Kite Announces Plans For New State-of-the-Art Facility To Expand Cell Therapy Production Capabilities

Kite Announces Plans For New State-of-the-Art Facility To Expand Cell Therapy Production Capabilities

Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer.

Gilead Sciences To Release First Quarter 2019 Financial Results On Thursday, May 2, 2019

Gilead Sciences To Release First Quarter 2019 Financial Results On Thursday, May 2, 2019

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes.

The Economy is Riding the Rails: Cramer's 'Mad Money' Recap (Wednesday 4/17/19)

The Economy is Riding the Rails: Cramer's 'Mad Money' Recap (Wednesday 4/17/19)

If you want a good read on the economy, look at the details of CSX's latest earnings report.

Nvidia, Advanced Micro Devices, Constellation: 'Mad Money' Lightning Round

Nvidia, Advanced Micro Devices, Constellation: 'Mad Money' Lightning Round

Jim Cramer weighs in on Nvidia, Advanced Micro Devices, Constellation Brands, Bausch Health, Arista Networks, Gilead Sciences and more.

Are These Stocks the Best of the Best?

Are These Stocks the Best of the Best?

Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.

Gilead And Insitro Announce Strategic Collaboration To Discover And Develop Novel Therapies For Nonalcoholic Steatohepatitis

Gilead And Insitro Announce Strategic Collaboration To Discover And Develop Novel Therapies For Nonalcoholic Steatohepatitis

Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH).

Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs

Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs

Gilead Sciences is partnering with Novo Nordisk to help combat liver disease.

TheStreet Quant Rating: C (Hold)